Supernus Pharmaceuticals SUPN Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Supernus Pharmaceuticals's accrued manufacturing costs?
- Supernus Pharmaceuticals (SUPN) reported accrued manufacturing costs of $24.21M in Q1 2026.
- How has Supernus Pharmaceuticals's accrued manufacturing costs changed year-over-year?
- Supernus Pharmaceuticals's accrued manufacturing costs increased by 37.6% year-over-year, from $17.6M to $24.21M.
- What is the long-term trend for Supernus Pharmaceuticals's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accrued manufacturing costs has grown at a 13.0% compound annual growth rate (CAGR), from $16.01M to $29.45M.